Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R). It was designed based on the native GIP sequence with modifications enabling GLP-1R co-agonism, creating a single molecule capable of engaging both incretin hormone pathways simultaneously. Its dual mechanism distinguishes it pharmacologically from selective GLP-1 receptor agonists.
Researchers have studied Tirzepatide for its effects on insulin secretion, glucagon suppression, and appetite regulation. The GIPR component has been of particular scientific interest, as preclinical evidence suggests GIP receptor agonism in the central nervous system may contribute to effects on food intake and body weight regulation. Research has examined how the combination of GIPR and GLP-1R signaling may produce complementary or synergistic metabolic effects.
Preclinical studies have investigated Tirzepatide’s effects on beta cell function, hepatic lipid content, and adipose tissue metabolism in animal models. Clinical research programs have generated extensive data on its cardiometabolic effects. Research has also examined its influence on heart failure markers, non-alcoholic steatohepatitis (NASH) endpoints, and obstructive sleep apnea parameters in clinical study contexts.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
